Melanoma Clinical Trials in San Antonio

Showing 141-160 of 203 trials

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

NCT01425008

This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.

MelanomaMetastatic MelanomaSolid Tumor+1 more

Millennium Pharmaceuticals, Inc.149 participantsStarted Sep 2011

San Francisco, California, United States • Denver, Colorado, United States • Augusta, Georgia, United States +13 more locations

COMPLETEDPhase 1< 1 mile

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse+4 more

Pfizer190 participantsStarted Jun 2011

Duarte, California, United States • La Jolla, California, United States • La Jolla, California, United States +39 more locations

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Melanoma Trials in Other Cities

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Other Conditions in San Antonio